Sørensen UBS

Aarhus University

2
Publications
33
h-index
(3,781 citations, 71 total works)

Research Topics

Pneumonia and Respiratory Infections (33)Streptococcal Infections and Treatments (18)Complement system in diseases (12)Neonatal and Maternal Infections (12)Glycosylation and Glycoproteins Research (9)

Alpha-gal Syndrome Publications

Isohemagglutinins exhibit synergistic polyreactivity toward Streptococcus pneumoniae surface antigens: implications for broad-spectrum reactivity of human antibodies.

Bernth Jensen JM, Søgaard OS, Petersen MS, Hoffmann S, Møller BK, et al.
Medical microbiology and immunology •

Synergistic polyreactivity of antibodies—where distinct oligo- or polyreactive clones combine to enable broad-spectrum antigen binding—was recently demonstrated for human anti-galactose-α-1,3-galactose (αGal) antibodies. However, it remains unclear whether this phenomenon also occurs in other antigen-defined antibody populations. Here, we investigated synergistic polyreactivity in isohemagglutinins (naturally occurring antibodies against ABO blood group antigens) and its potential role in antimicrobial defense. Isohemagglutinins were affinity-purified from pooled plasma from groups of healthy donors sharing the same ABO blood group, then characterized by solid-phase immunoassays, SDS-PAGE, and Western blotting. Binding to formaldehyde-fixed Streptococcus pneumoniae representing 30 serotypes was assessed by flow cytometry. Specificity was further examined using inhibition assays with soluble pneumococcal polysaccharides. To evaluate clinical relevance, ABO blood group types (used as proxies for isohemagglutinin profiles) were linked to serotype-specific invasive pneumococcal disease (IPD) events using Danish nationwide registry data. The purified isohemagglutinins retained specificity for their cognate ABO antigens. Notably, they bound all tested pneumococcal strains, primarily through reactivity with the common cell wall polysaccharide. Adsorption studies further revealed serotype-specific capsule binding mediated by distinct isohemagglutinin clones, demonstrating synergistic polyreactivity. Despite this, population-level analyses showed only modest protection: most notably, individuals with blood types B or O (producers of anti-A and anti-A,B isohemagglutinins, respectively) had a 19% lower prevalence of serotype 9V IPD than blood type A or AB individuals. Although the overall protective effect of isohemagglutinins against IPD seems limited, the observed synergistic polyreactivity supports the concept that this is a general feature of antigen-defined antibodies, extending beyond anti-αGal antibodies.

Impact of Staphylococcus aureus colonization and skin abscesses on formation of human anti-αGal antibodies.

Bernth Jensen JM, Dinh KM, Hindhede L, Erikstrup LT, Hansen AG, et al.
Medical microbiology and immunology •

IgG antibodies against terminal galactose-α-1,3-galactose (anti-αGal antibodies) are naturally occurring in humans, but their origins remain poorly understood. These antibodies target various microorganisms including Staphylococcus aureus, a common nasal commensal and the major cause of skin abscesses. This study investigates the impact of S. aureus colonization and abscess events on plasma anti-αGal antibody levels. We measured plasma anti-αGal antibody levels using a quantitative immunoassay in: (i) 101 pairs of healthy individuals with and without nasal S. aureus colonization, (ii) 106 healthy individuals before and after abscess formation, and (iii) 43 patients with recurrent skin abscesses compared with 75 patient controls and 60 healthy controls. We observed a 35% reduction (95%CI: 7-54%) in anti-αGal antibody levels in nasal S. aureus carriers. Conversely, we found a 30% increase (95%CI: 4-66%) in individuals within 187 days post-skin abscess, and patients with recurrent skin abscesses exhibited 81% higher (95%CI: 14-190%) levels than patient controls, and 110% higher (95%CI: 39-230%) than healthy controls. This study suggests that skin abscesses lead to elevated plasma anti-αGal antibody levels and that these antibodies might convey or correlate with mucosal immunity to S. aureus.